MedTech Acquisition (MedTech Acquisition) Risk Assessment

View and export this data going back to 2020. Start your Free Trial

What is MedTech Acquisition Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of MedTech Acquisition is: No Data: Cannot be evaluated.

Competitive Comparison of MedTech Acquisition's Risk Assessment

For the Shell Companies subindustry, MedTech Acquisition's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MedTech Acquisition's Risk Assessment Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, MedTech Acquisition's Risk Assessment distribution charts can be found below:

* The bar in red indicates where MedTech Acquisition's Risk Assessment falls into.

MedTech Acquisition (NAS:MTACU) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

MedTech Acquisition Risk Assessment Related Terms

Thank you for viewing the detailed overview of MedTech Acquisition's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

MedTech Acquisition (MedTech Acquisition) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » MedTech Acquisition Corp (NAS:MTACU) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

48 Maple Avenue, Greenwich, CT, USA, 06830

Website

MedTech Acquisition Corp is a blank check company.

Executives

Magnetar Financial Llc	10 percent owner	1603 ORRINGTON AVE., 13TH FLOOR, EVANSTON IL 60201
Magnetar Capital Partners Lp	10 percent owner	1603 ORRINGTON AVE., 13TH FLOOR, EVANSTON IL 60201
Supernova Management Llc	10 percent owner	1603 ORRINGTON AVENUE, 13TH FLOOR, EVANSTON IL 60201
David J. Snyderman	10 percent owner	C/O MAGNETAR FINANCIAL LLC, 1603 ORRINGTON AVENUE, 13TH FLOOR, EVANSTON IL 60201
David L Treadwell	director	222 S 15TH STREET, SUITE 600 N, OMAHA NE 68102
Manuel Aguero	director	600 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10022
Thierry B. Thaure	director	3957 POINT EDEN WAY, HAYWARD CA 94545
David J Matlin	director, 10 percent owner, officer: Chief Financial Officer
Karim Karti	director	C/O IRHYTHM TECHNOLOGIES, INC., 650 TOWNSEND STREET, SUITE 500, SAN FRANCISCO CA 94103
Christopher C Dewey	director, 10 percent owner, officer: Chief Executive Officer	120 BROADWAY, 27TH FLOOR, NEW YORK NY 10271
Robert H. Weiss	officer: Chief Admin Officer and Sec.	585 WEED STREET, NEW CANAAN CT 06840
Maurice R Ferre	director	C/O MAKO SURGICAL CORP., 2555 DAVIE ROAD, FORT LAUDERDALE FL 33317
Ivan Delevic	director	C/O MAKO SURGICAL CORP., 2555 DAVIE ROAD, SUITE 110, FORT LAUDERDALE FL 33317
Medtech Acquisition Sponsor Llc	10 percent owner	1345 AVENUE OF THE AMERICAS, NEW YORK NY 10105
Martin William Roche	director	600 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10022